Trxade Health featured on NASDAQ tower on 10/29/2015.

Trxade Health Retains Investor Relations Partners

Trxade Health featured on NASDAQ tower on 10/29/2015 in Times Square NY.

TAMPA, Fla., Oct. 29, 2015 (GLOBE NEWSWIRE) — Trxade Health, Inc. (OTCQB:TRXD), a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers nationally, today announced that it has retained Investor Relations Partners (IRP) to expand the Company’s strategic investor relations program.

“This is an exciting time for Trxade Health and we believe with the help of Investor Relations Partners we will be able to more broadly and effectively communicate our story to the investment community,” said Suren Ajjarapu, Chairman and CEO of Trxade Health. “We have a number of exciting developments at Trxade Health driven by our proprietary technology that is designed to disrupt the multi-billion dollar pharmaceutical marketplace. Based on our current double-digit revenue growth rates and increasing demand for our services, we expect 2016 to be a profitable and breakthrough year for Trxade and its shareholders and look forward to updating the market on our progress as we continue to execute on our business plan,” concluded Mr. Ajjarapu.

Todd Markey, Vice President of Investor Relations Partners, said, “We are looking forward to communicating Trxade Health’s investment story to beyond its existing shareholder base and the health care sector. We believe Trxade Health should be of particular interest to value and earnings growth investors given our belief that the company is significantly undervalued when considering the vast potential of its proprietary disruptive technology and its outlook for accelerated growth and profitability,” concluded Mr. Markey.

To be added to Trxade Health’s investor lists, please contact Todd Markey at Investor Relations Partners at 818-280-6800 or via email at

About Investor Relations Partners, Inc.

Investor Relations Partners, Inc. (IRP) is a full-service investor relations firm serving clients from Los Angeles to New York to China. The principals of IRP have received top industry awards for their investor relations programs for a number of high-profile companies, including, but not limited to, Starwood Hotels & Resorts Worldwide, ValueVision Media, Taro Pharmaceuticals, and LJ International. The firm’s principals have executed effective investor relations programs for dozens of public companies, ranging from emerging micro-cap companies to multinational corporations with market capitalizations in excess of $15 billion. For further information on IRP, please visit the firm’s Website at

About Trxade Health, Inc.

Headquartered in Tampa, Florida, Trxade Health, Inc. (OTCQB:TRXD) is a web based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services. Founded in 2010, Trxade Health currently operates the trading platform with 4,600 registered members. Trxade Health also distributes directly private label pharmaceuticals through their 100% subsidiary, Westminster Pharmaceuticals LLC, to these registered members. For additional information please visit us at

Disclaimer & Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. Except as may be required by applicable law, we assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The company undertakes no duty to update forward-looking statements.

Investor Relations Contact:
Max Pashman
Phone: 818-280-6800

See more at:

The Future of the Pharmacy World

The Future of the Pharmacy World

The Future of the Pharmacy World

Technology, Knowledge, Medicine

The wave of the future may not include the hover boards as predicted in the popular, 1989 film, Back To The Future II, but the Pharmacy World will be seeing the implementation of tele-pharmacies, pharmacogenomics, smart lenses and the use of radio frequency technology. An incredible service that is being discussed is using radio frequencies via beacons in the parking lot of a pharmacy that will alert the pharmacist via an iPad of typical products that patient buys. This can help increase profitability and repeat customers. As you can see the Pharmacy world is growing and changing rapidly. As independent pharmacists it’s important to stay informed and progress with the times. “The pharmacist’s role has grown and evolved over the years to become more inclusive of patients’ health care needs as a whole. Patients can now look to their pharmacy as a total health care provider, and today’s pharmacists play an important role in improving patient outcomes…

Pharmacists are definitely thinking, talking, and evaluating what the future holds for their profession in the context of all the recent sweeping changes in health care policy” (Pharmacy Times). Dan Benamoz, RPh and CEO of the Palm Beach, FL-based Pharmacy Development Services shared that Alcon and Google are creating a “smart contact lens” that will revolutionize the way patients manage their Diabetes. This lens will be a minimally invasive way to continuously monitor blood glucose levels from a patient’s lacrimal fluid which will communicate these readings with a mobile device via Wi-Fi. Another product, the Hololens by Microsoft, allows Pharmacists to access medical information and prescription information via eyeglasses. It took 5 years to develop and was announced in early 2015. This gives Pharmacists the ability to give immediate counseling and education to patients.

Pharmacogenomics, or the study of the role of genetics predicting drug response, is another up-and-coming theme for Pharmacists and Providers. “The DNA Medical Institute created rHealth, a portable handheld device that can diagnose hundreds of diseases using a single drop of blood. Now, we could be looking at biomarkers to identify early indicators of serious ailments. I think the technology will be used by national labs such as Quest Diagnostics”, Benamoz stated (Drug Topics). About ten million people are currently using tele-pharmacy services, and the number is rising, especially due to the Obama Administration endorsing it. To stay competitive, it’s good to think about offering this service to patients, but make sure the Pharmacy Board in your state approve.

Extra: Step Into The Future With USF’s Health Pharmacy Plus

Not too far from Trxade headquarters, University of South Florida in Tampa is introducing Pharmacy Plus. The Pharmacy of the Future revolutionizes the Pharma industry and catapults it into the future with tools to improve and maximize profits, while minimizing risks. USF Health Pharmacy Plus is a national prototype giving us a preview of what may become the standard for the future, today.

Below are some bullet points from USF’s website on how using technology, knowledge, and medicine the pharmacy of the future plans to improve the quality of the patient’s needs.

Imagine a future where:

+ The pharmacist plays an integral role on your healthcare team.
+ You keep the healthy conversation going with both technology and human interaction.
+ It’s about more than taking a pill. It’s about how we will use innovative new tools to help you live healthier.
+ You receive health advice from your mobile device.
+ Your doctor’s prescription sends you to an online, multimedia learning experience as often as it does to the pharmacy.
+ Medication is personalized specifically for you.
+ You can check your health as easily as you check your email.

YouTube Video:

Old Drugs, New Uses Is A Trend

Old Drugs, New Uses Is A Trend

Old Drugs, New Uses Is A Trend

Ursodeoxycholic Acid

It is becoming more and more common to prescribe existing drugs for new uses. Take Lyrica for example; this drug was originally used to treat depression, but it was later discovered that it has therapeutic effects for patients that suffer from pain disorders, such as Fibromyalgia.

This same concept is being suggested for another drug called Ursodeoxycholic Acid (UDCA) or Actigall. The intended use of this drug is for liver disease. It has successfully reduced liver jaundice, ascites, and biliary stasis in patients for decades. It is now believed that this medication can actually slow the onset and progression of Parkinson’s disease. Researchers from the Sheffield Institute of Translational Neuroscience (SITraN) and the University of York studied the effects of this drug on mutated nerve cells of the LRRK2 gene in fruit flies.

This mutation is the most common cause of inherited Parkinson’s disease. Mitochondria in each cell gives the cell energy it needs to function. The LRRK2 mutation prevents mitochondria from functioning properly, leaving is susceptible to neurological diseases, like Parkinson’s. It is estimated that at least 500,000 people in the U.S. have Parkinson’s disease.

Dr. Heather Mortiboys of SITraN reports; "We demonstrated the beneficial effects of UDCA in the tissue of LRRK2 carriers with Parkinson’s disease as well as currently asymptomatic LRRK2 carrier. In both cases, UDCA improved mitochondrial function as demonstrated by the increase in oxygen consumption and cellular energy levels” (Medical News Today).

Expect this drug to be in high demand in the near future.

Trxade Prime: Time Saving Tools

  • Compare Up To 50 NDCs At Once (With Easy Access to Shopping Cart)
  • See Immediate Savings
  • Includes Best Value Recommendations (Different Strength, Package Size, Manufacturers, Etc.)

Trxade Prime

Free Concierge Service:

Before you buy from your Primary, send us your daily order and we’ll price compare for you. Include NDCs, product name, quantity needed, & current price (optional). Your Account Manager will review the results and follow up with you to ensure you maximize your Trxade savings. Concierge Fax: 1-800-265-6932

Extra: See Pharmacy Acquisition Cost (PAC) at no additional cost. PAC pricing is the national average price for pharmaceutical products at the pharmacy level and is an excellent way to determine fair prices. Trxade has PAC built into its online marketplace making it easier to buy smarter.


FDA Review of the use of Codeine for Kids

FDA Review of the use of Codeine for Kids

The European Medicines Agency (EMA) bold statement regarding the use of codeine in children has a struck a cord with the U.S. Food and Drug Administration (FDA).  The EMA states that codeine should not be used for children under the age 12. Codeine is an opioid analgesic used to treat pain that can also be found in children’s cold and cough medicine. Codeine is metabolized by the body and turns into morphine. It is a central nervous system depressant that can have dangerous side effects that include; slowed breathing, drowsiness, nausea, vomiting, sedation, addiction, bradycardia, syncope, hallucinations, seizures, anaphylaxis, and even death.

Eric Pahon with the FDA in response to EMA’s codeine declaration, “We have looked at their data and feel it is well-presented and seems firm. We are not really recommending anything at the moment. The FDA will continue to evaluate this safety issue and will consider the EMA recommendations”. In the FDA’s defense, they did issue a warning to physicians in 2013 that advised not to prescribe codeine for children after a tonsillectomy/adenoidectomy due to a higher risk of breathing complications. But was this warning heard? Was it sufficient?

Since 1999, the FDA reports that 10 children have died and 3 have overdosed on Codeine. The American Academy of Pediatrics is against giving codeine in a cough suppressant. In 2007, the FDA did however talk many pharmaceutical companies into taking over-the-counter (OTC) cold and cough drugs off the market for infants. We can’t stop physicians from prescribing these medications to our patients, but we can make sure we thoroughly educate the parents of these children on the dangers of Codeine. We can also educate parents on specific signs and symptoms to look for that may indicate a problem, such as, labored or loud breathing, confusion, and fatigue.